A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(8 sites)

United States

GSK Investigational Site, Lenexa, Kansas

GSK Investigational Site, Secaucus, New Jersey

GSK Investigational Site, Rochester, New York

GSK Investigational Site, Weatherford, Texas

GSK Investigational Site, Seattle, Washington

GSK Investigational Site, Wenatchee, Washington

South Africa

GSK Investigational Site, Johannesburg

GSK Investigational Site, Soshanguve